Live
- Guv invites Soren to form govt
- Mahayuti allies go into huddle to pick Maha CM
- Rachakonda police issues prohibitory orders in view of TGPSC tests
- SBI rescues sr citizen from `46L cyber fraud
- 12-yr-old dies of electrocution
- Installation of smart meters opposed
- State Cabinet expansion in focus as CM leaves for Delhi
- Need to reintroduce country’s forgotten pride: Bhagwat
- Pant shatters Iyer's IPL auction record, sold to Super Giants for Rs 27 cr
- Yuva Sangeetha Sammelanam held
Just In
Japanese firm ties up with Biological E to make dengue vaccine
New Delhi: Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The...
New Delhi: Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organisation to achieve zero case-fatality rate due to dengue by 2030, the company said in a statement.
Announcing the partnership Telangana Chief Minister Anumula Revanth Reddy said Hyderabad will host the facility where the dengue vaccine, a result of the partnership between Takeda and Biological E, will be manufactured. The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine, it added. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade, it said.
"We are proud to announce a strategic manufacturing partnership with Biological E Ltd which has deep expertise in vaccine manufacturing and longstanding support of public health programmes around the world," Takeda President of the Global Vaccine Business Unit Gary Dubin said in a statement.
Together, the entities will help combat dengue on a global scale by significantly increasing manufacturing capacity for multi-dose vials of TAK-003 (vaccine) to drive sustainable access in more endemic countries, he added. As the fastest-spreading mosquito-borne viral disease, about half of the world's population is now at risk of dengue. In India and Southeast Asia, 1.3 billion people live in dengue-endemic areas, with Thailand, India, and Indonesia among some of the most highly endemic countries.
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com